Two cardiometabolic-related news items have been observed: Nemaura Medical published its CY Q4 ’20 (FY Q3 ’21) earnings update and Metacrine announced the results of the MET409 proof-of-concept study were published in the Journal of Hepatology. Below, FENIX provides highlights and insights for the respective news items.
Seven cardiometabolic-related news items have recently been observed from AstraZeneca, Dexcom, Supersapiens, Regeneron, Hepion Pharmaceuticals, and Teva. Below, FENIX provides highlights and insights for the respective news items.
Two diabetes-related news items have been observed: Dexcom announced the debut of its first-ever Super Bowl commercial; and Pfizer hosted its Q4 ’20 earnings call, commenting on its oral GLP-1 pipeline developments. Below, FENIX provides highlights and insights for the respective news items, including thoughts on how the Dexcom Super Bowl commercial signals that Dexcom is ready to move on the CGM mass market opportunity.
Two diabetes-related news items have been observed: Senseonics announced its partner, Ascensia, has reinitiated EU commercial activities for the Eversense XL implantable CGM system; and Nemaura Medical announced the appointment of Jay Warner as Head of US Commercial Operations. Below, FENIX provides highlights and insights for the respective news items, including the curious mention of Livongo in the Nemaura press release.
A series of diabetes-related news items have been observed: Abbott hosted its Q4 and FY ’20 earnings call; Abbott recently published an article on its website titled “FreeStyle Libre 2 Puts NBA Legend Ray Allen at Ease;” the Apple Watch Series 7 and the Samsung Galaxy Watch4 are both reportedly going to feature glucose monitoring; and DarioHealth announced its acquisition of Upright Technologies, a digital musculoskeletal company. Below, FENIX provides highlights and insights for the respective news items.
Two diabetes-related news items have been observed: Oramed has begun randomizing patients into its Ph3 ORMD-0801 T2DM study (view press release) and Dario announced the hiring of Chris Chan as the company’s new SVP of employer sales (view press release). Below, FENIX provides highlights and insights from the respective news items.
A series of cardiometabolic-related news items have been observed: Metacrine announced FDA granted Fast Track designation to MET642 for the treatment of NASH; Senseonics announced a positive coverage decision for its implantable CGM from EmblemHealth; and yesterday, Insulet announced the Canadian launch of Omnipod DASH. Below, FENIX provides highlights and insights for the respective news items.
On day two of JPM 2021, FENIX has provided coverage of presentations by Lilly, Novo Nordisk, Abbott, Insulet, Amarin, and Ionis. Additionally, one separate cardiometabolic-related news item has been observed: Bayer announced FDA granted priority review of finerenone for patients with DKD. Below, FENIX provides a topline summary of key takeaways followed by more in-depth coverage.
On the first day of JPM 2021, FENIX has provided coverage of presentations by major cardiometabolic companies including Dexcom, Medtronic, Teladoc, and Novartis. Additionally, three separate cardiometabolic-related news items have been observed: BI/Lilly announced FDA has accepted the Jardiance sNDA for the reduction of HFrEF in patients with and without T2DM; Dexcom and Teladoc announced the pilot launch of the new “CGM-powered insights” feature for Livongo for Diabetes users; and Adocia filed a patent for cell therapy in patients with T1DM. Below, FENIX provides a topline summary of key takeaways by company followed by more in-depth coverage.
Two diabetes-related news items have been observed: the CT.gov record for Lifescan/Sanvita Medical’s CGM pilot study has been updated to reflect an October 2020 completion; and Lupin Limited announced it received tentative FDA approval for 5mg/1000mg, 10mg/1000mg, 12.5mg/1000mg, and 25mg/1000mg empagliflozin + metformin XR tablets. Below, FENIX provides highlights and insights for the respective news items.